Description: NeuroRx, Inc. operates as a clinical stage-small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders. Its drug candidate includes Cyclurad, an oral therapeutic for the treatment of acute/elevated suicidal ideation/crisis in bipolar depression. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.
Home Page: www.nrxpharma.com
NRXP Technical Analysis
1201 Orange Street
Wilmington,
DE
19801
United States
Phone:
484 254 6134
Officers
| Name | Title |
|---|---|
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist & Director |
| Mr. Robert Besthof M.I.M. | Head of Operations, Chief Commercial & Patient Officer |
| Mr. Stephen H. Willard Esq. | CEO & Director |
| Prof. Daniel C. Javitt | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Seth L. Van Voorhees Ph.D. | CFO & Treasurer |
| Suzanne Messere | Investor Relations |
| Dr. Michael Kunz | Gen. Counsel & Corp. Sec. |
| Ms. Molly Cogan | Sr. Director of Global Communications & Gov. Affairs |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist |
| Dr. Dennis K. McBride Ph.D. | Chief Strategy Officer & Sr. Scientist |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.5546 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-12-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |